{"prompt": "['CONFIDENTIAL', '204878 (ZOSTER-064)', 'Protocol Administrative Change 3 Final', 'Study Protocol', 'gsk', 'Sponsor:', 'GlaxoSmithKline Biologicals SA', \"Rue de l'Institut 89, 1330 Rixensart, Belgium\", 'eTrack study number and', '204878 (ZOSTER-064)', 'Abbreviated Title', 'Investigational New Drug', 'BB-IND-13857', '(IND) number', 'Date of protocol', 'Final: 29 January 2018', 'Date of protocol', 'Amendment 1 Final: 17 October 2018', 'amendment', 'Date of protocol', 'Administrative Change 1 Final 27 March 2018', 'administrative change', 'Administrative Change 2 Final: 13 November 2018', 'Administrative Change 3 Final 11 February 2019', 'Title', 'Observational study to assess frailty of subjects during', 'ZOSTER-006 and ZOSTER-022.', 'Detailed Title', 'Observational study to assess frailty of subjects during', 'ZOSTER-006 and ZOSTER-022 and HZ efficacy,', 'immunogenicity and safety of HZ/su by frailty status.', 'Co-ordinating author(s)', 'PPD', 'Lead Scientific Writer', ',', 'PPD', 'Senior Scientific Writer', ',', 'PPD', ',', 'Scientific Writer, XPE Pharma', '& Science for GSK Biologicals', 'PPD', 'Scientific Writer, XPE Pharma', '& Science for GSK Biologicals (Administrative', 'Change 3, 11 Feb 2019)', 'Contributing authors', 'PPD', 'Clinical Research and', ',', 'Development Lead', 'PPD', ',', 'Study Delivery Lead', 'PPD', 'Lead Statistician', ',', 'PPD', 'Lead Statistician', ',', 'PPD', ', Oversight Data Management', '11-FEB-2019', '1', '70882527ffe6806e42bab9a20b06541da11028ce']['CONFIDENTIAL', '204878 (ZOSTER-064)', 'Protocol Administrative Change 3 Final', 'eTrack study number and', '204878 (ZOSTER-064)', 'Abbreviated Title', 'Investigational New Drug', 'BB-IND-13857', '(IND) number', 'Detailed Title', 'Observational study to assess frailty of subjects during', 'ZOSTER-006 and ZOSTER-022 and HZ efficacy,', 'immunogenicity and safety of HZ/su by frailty status.', 'Contributing authors', 'PPD', 'Director Value Evidence', ',', '(cont.)', 'PPD', 'Health Economics Biostatistician', ',', 'PPD', 'Global Regulatory Affairs', '(Administrative Change 3, 11 Feb 2019)', 'PPD', ',', 'Clinical and Epidemiology Project', 'Lead (CEPL) for Zoster, US RDC', \"GSK Biologicals' protocol template for observational studies and interventional\", 'studies without administration of medicinal products as described in a research', 'protocol based on the Protocol Document Standard version 15.0', 'C', '2018 - 2019 GSK group of companies or its licensor.', '11-FEB-2019', '2', '70882527ffe6806e42bab9a20b06541da11028ce']['CONFIDENTIAL', '204878 (ZOSTER-064)', 'Protocol Administrative Change 3 Final', 'Protocol Administrative Change 3 Sponsor Signatory Approval', 'eTrack study number and', '204878 (ZOSTER-064)', 'Abbreviated Title', 'IND number', 'BB-IND-13857', 'Date of protocol', 'Administrative Change 3 Final: 11 February 2019', 'administrative change', 'Detailed Title', 'Observational study to assess frailty of subjects', 'during ZOSTER-006 and ZOSTER-022 and HZ', 'efficacy, immunogenicity and safety of HZ/su by', 'frailty status.', 'Sponsor signatory', 'Anne Schuind, Clinical and Epidemiology Project', 'Lead for Zoster, GlaxoSmithKline Biologicals, US', 'RDC', 'Signature', 'Date', 'For internal use only', 'Checksum', '!Ver.!Created On', '-', '70882527ffe6806e42bab9a20b06541dal1028ce 2.0 2/14/2019 1:02:54 PM -', '-', '11-FEB-2019', '3', '70882527ffe6806e42bab9a20b06541da11028ce']\n\n###\n\n", "completion": "END"}